Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome.
OBJECTIVE
To evaluate the effectiveness of sibutramine therapy alone and in combination with ethinyl estradiol-cyproterone acetate (EE-CPA) on the clinical and metabolic parameters of obese women with polycystic ovary syndrome (PCOS).


METHODS
Prospective randomized, controlled study.


METHODS
Endocrinology and gynecology clinics.


METHODS
Forty obese women with PCOS.


METHODS
Group 1 was treated with oral EE-CPA (35 microg-2 mg/day), group 2 with oral sibutramine (10 mg/day), and group 3 with a combination of EE-CPA plus sibutramine for 6 months. All groups were advised to consume a diet of 1200 kcal/day.


METHODS
Measurements were performed before and 6 months after treatment of body mass index, waist-to-hip ratio, systolic and diastolic blood pressure, Ferriman-Gallwey hirsutism score, total testosterone, free testosterone, sex hormone-binding globulin, dihydroepiandrosterone sulfate (DHEAS), total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, glucose and insulin during oral glucose tolerance test, and insulin sensitivity index; area under the curve for glucose and insulin were obtained from OGTT.


RESULTS
Body mass index, Ferriman-Gallwey hirsutism score, serum total testosterone, free testosterone, and DHEAS levels were significantly decreased and SHBG was significantly increased in all groups at the end of the study. WHR, diastolic blood pressure, and serum triglyceride level were significantly reduced only in the sibutramine group.


CONCLUSIONS
Sibutramine might have a positive effect on hyperandrogenemia, and clinical and metabolic risk factors for cardiovascular disease in obese women with PCOS.
Sabuncu
Tevfik
T
Endocrinology and Metabolism Department, University of Harran, Faculty of Medicine, Sanliurfa, Turkey. sabuncu@ixir.com
Harma
Muge
M
Harma
Mehmet
M
Nazligul
Yasar
Y
Kilic
Feryal
F
D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use*; D001794:Blood Pressure; D001824:Body Constitution; D001835:Body Weight / Q000187:drug effects; D003503:Cyclobutanes / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D003971:Diastole; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006628:Hirsutism / Q000209:etiology; D006728:Hormones / Q000097:blood; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D000726:Androgen Antagonists; D001067:Appetite Depressants; D003503:Cyclobutanes; D004338:Drug Combinations; D006728:Hormones; D014280:Triglycerides; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C058254:sibutramine